Your browser doesn't support javascript.
loading
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease.
Campochiaro, Corrado; Cavalli, Giulio; Farina, Nicola; Tomelleri, Alessandro; De Luca, Giacomo; Dagna, Lorenzo.
Affiliation
  • Campochiaro C; Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy campochiaro.corrado@hsr.it.
  • Cavalli G; Vita-Salute San Raffaele University, Milan, Italy.
  • Farina N; Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy.
  • Tomelleri A; Vita-Salute San Raffaele University, Milan, Italy.
  • De Luca G; Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy.
  • Dagna L; Vita-Salute San Raffaele University, Milan, Italy.
Ann Rheum Dis ; 81(1): e11, 2022 01.
Article in En | MEDLINE | ID: mdl-31818808
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Erdheim-Chester Disease Limits: Humans Language: En Journal: Ann Rheum Dis Year: 2022 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Erdheim-Chester Disease Limits: Humans Language: En Journal: Ann Rheum Dis Year: 2022 Document type: Article